From 1 September 2026, the prescriber accreditation requirement for hepatitis B medicines under the PBS Section 100 (s100) Highly Specialised Drugs Program will be removed. As a result, all medical and authorised nurse practitioners will be able to prescribe hepatitis B antiviral treatment without additional specialist accreditation. ASHM is currently updating its website, education and resources to reflect this change.

Find out more

Back

HCV In Children: Australian Commentary On AASLD-IDSA Guidance

First published:

March 2025

Last published:

2024

Overview

This document provides Australian (AU) Commentary on the AASLD-IDSA HCV Guidance: HCV in Children. Recommendations for testing, managing, and treating hepatitis C. Australian commentary has only been provided where needed in order to provide additional clarification or detail variations found in the Australian setting. Topics cover testing; transmission and prevention; monitoring and medical management; whom and when to treat among children and adolescents with HCV infection; and HCV antiviral therapy for children and adolescents.